晚期胃癌的新辅助治疗策略：当前创新与未来挑战
Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges.
作者信息
Zhu Zhi, Gong Ying-Bo, Xu Hui-Mian
机构信息
Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
出版信息
Chronic Dis Transl Med. 2020 Apr 23;6(3):147-157. doi: 10.1016/j.cdtm.2020.03.004. eCollection 2020 Sep.
Abstract
Gastric cancer, which has a high incidence and poor prognosis, remains a therapeutic challenge. Recently, neoadjuvant therapy has attracted increasing attention due to high recurrence rate and low survival rate after resection in most patients with advanced stage. Clinical trials show that neoadjuvant approaches confer a significant survival advantage for resectable locally advanced gastric cancer. The specific advantages of chemoradiotherapy compared with chemotherapy have not been clarified; optimal regimens and cycles, particularly in the preoperative setting, should be studied further; and trials aimed at determining the role of targeted and immunological therapies should be conducted.
摘要
胃癌发病率高且预后较差，仍然是一个治疗难题。近年来，由于大多数晚期患者术后复发率高、生存率低，新辅助治疗受到越来越多的关注。临床试验表明，新辅助治疗方法可为可切除的局部晚期胃癌带来显著的生存优势。与化疗相比，放化疗的具体优势尚未明确；应进一步研究最佳方案和周期，尤其是在术前阶段；并且应开展旨在确定靶向治疗和免疫治疗作用的试验。
相似文献
1
Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges.晚期胃癌的新辅助治疗策略：当前创新与未来挑战
Chronic Dis Transl Med. 2020 Apr 23;6(3):147-157. doi: 10.1016/j.cdtm.2020.03.004. eCollection 2020 Sep.
2
Neoadjuvant therapy for gastric cancer: current evidence and future directions.胃癌的新辅助治疗：当前证据与未来方向。
J Gastrointest Oncol. 2015 Oct;6(5):534-43. doi: 10.3978/j.issn.2078-6891.2015.047.
3
Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer.根据局部晚期低位直肠癌患者术前化疗反应预测预后。
BMC Cancer. 2019 Dec 16;19(1):1222. doi: 10.1186/s12885-019-6424-4.
4
Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.多西他赛、顺铂和S-1新辅助化疗用于可切除局部进展期胃癌的有效性
Med Oncol. 2017 Aug;34(8):139. doi: 10.1007/s12032-017-0997-z. Epub 2017 Jul 13.
5
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.手术和术前化疗后可切除胃癌的化疗与放化疗（CRITICS）：一项国际、开放标签、随机 3 期试验。
Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.
6
[The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma].[辅助和新辅助化疗在胃癌治疗中的价值]
Wien Klin Wochenschr. 1996;108(16):496-504.
7
Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.术前短程放疗序贯新辅助化疗治疗局部进展期直肠癌的剂量递增：一项开放标签、单中心、I 期临床试验方案。
BMJ Open. 2019 Mar 23;9(3):e025944. doi: 10.1136/bmjopen-2018-025944.
8
Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.局部晚期胰腺癌的术前化疗、放疗及手术切除
Arch Surg. 2000 Jan;135(1):81-7; discussion 88. doi: 10.1001/archsurg.135.1.81.
9
Role of (chemo)-radiotherapy in resectable gastric cancer.（化疗）放疗在可切除胃癌中的作用。
Clin Oncol (R Coll Radiol). 2014 Sep;26(9):541-50. doi: 10.1016/j.clon.2014.06.004. Epub 2014 Jul 1.
10
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.网络荟萃分析比较新辅助放化疗、新辅助化疗和直接手术治疗可切除、交界可切除和局部进展期胰腺导管腺癌患者的疗效。
Radiat Oncol. 2019 Jul 10;14(1):120. doi: 10.1186/s13014-019-1330-0.
引用本文的文献
1
ASO Author Reflections: Lost in Transition: Addressing Preventable Attrition after Neoadjuvant Chemotherapy.ASO作者反思：在过渡中迷失：解决新辅助化疗后可预防的患者流失问题
Ann Surg Oncol. 2025 Jul 20. doi: 10.1245/s10434-025-17887-5.
2
Predictive Value of Tumor Regression Grading on the Prognosis of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.肿瘤退缩分级对局部进展期胃癌新辅助化疗预后的预测价值：一项系统评价和Meta分析
Clin Transl Gastroenterol. 2025 May 14;16(7):e00860. doi: 10.14309/ctg.0000000000000860. eCollection 2025 Jul 1.
3
Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.新辅助贝伐单抗联合化疗在局部晚期胃癌患者中的疗效和安全性：一项回顾性比较研究
World J Surg Oncol. 2025 Jan 28;23(1):26. doi: 10.1186/s12957-024-03624-x.
4
Efficacy and safety of gastroscopic hemostasis in the treatment of acute gastric hemorrhage: A meta-analysis.胃镜止血治疗急性胃出血的疗效与安全性：一项荟萃分析。
World J Gastrointest Oncol. 2023 Nov 15;15(11):1988-1997. doi: 10.4251/wjgo.v15.i11.1988.
5
Nab-paclitaxel plus S-1 oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study).纳米紫杉醇联合S-1与奥沙利铂联合S-1作为晚期胃癌一线治疗的多中心、随机、III期试验（GAPSO研究）结果
Ther Adv Med Oncol. 2022 Aug 12;14:17588359221118020. doi: 10.1177/17588359221118020. eCollection 2022.
6
DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?用于预测铂类化疗反应的DNA甲基化生物标志物：我们目前的进展如何？
Cancers (Basel). 2022 Jun 13;14(12):2918. doi: 10.3390/cancers14122918.
7
Association of dysbindin expression with individualized postoperative prognosis and chemotherapy benefit among patients with gastric adenocarcinoma.胃腺癌患者中dysbindin表达与个体化术后预后及化疗获益的相关性
J Cancer. 2021 Sep 21;12(22):6740-6748. doi: 10.7150/jca.60576. eCollection 2021.
8
Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM).胃癌 CT 影像学报告结构化和共享：意大利胃癌研究组（GIRCG）和意大利医学与介入放射学会（SIRM）的共识建议。
Eur Radiol. 2022 Feb;32(2):938-949. doi: 10.1007/s00330-021-08205-0. Epub 2021 Aug 12.
9
Expression and mechanism of exosome-mediated A FOXM1 related long noncoding RNA in gastric cancer.外泌体介导的 FOXM1 相关长非编码 RNA 在胃癌中的表达及机制。
J Nanobiotechnology. 2021 May 10;19(1):133. doi: 10.1186/s12951-021-00873-w.
10
Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients.组合式双药递送系统以加强对胃癌患者的护理和治疗。
Drug Deliv. 2020 Dec;27(1):1491-1500. doi: 10.1080/10717544.2020.1822460.
本文引用的文献
1
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.随机 ST03 试验中围手术期化疗治疗胃癌和胃食管交界癌的手术质量保证。
Br J Surg. 2019 Aug;106(9):1204-1215. doi: 10.1002/bjs.11184. Epub 2019 Jul 3.
2
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗（FLOT4）：一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
3
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach.《2018年韩国胃癌诊疗指南：基于证据的多学科方法》
J Gastric Cancer. 2019 Mar;19(1):1-48. doi: 10.5230/jgc.2019.19.e8. Epub 2019 Mar 19.
4
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer.中国临床肿瘤学会（CSCO）：胃癌诊断与治疗临床实践指南。
Cancer Commun (Lond). 2019 Mar 18;39(1):10. doi: 10.1186/s40880-019-0349-9.
5
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).随机 III 期临床试验：胃切除术联合或不联合新辅助 S-1 加顺铂治疗 4 型或大型 3 型胃癌的短期安全性和手术结果：日本临床肿瘤学组研究（JCOG0501）。
Gastric Cancer. 2019 Sep;22(5):1044-1052. doi: 10.1007/s10120-019-00941-z. Epub 2019 Mar 2.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?血清生存素表达是否可作为局部进展期胃癌患者接受新辅助化疗的预测生物标志物？
Cancer Biomark. 2018;22(1):143-149. doi: 10.3233/CBM-171119.
8
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).未经选择的局部晚期胃食管腺癌患者围手术期化疗联合或不联合表皮生长因子受体阻断：德国癌症学会（AIO/CAO STO-0801）的高级生物标志物计划的随机 II 期研究。
Eur J Cancer. 2018 Apr;93:119-126. doi: 10.1016/j.ejca.2018.01.079. Epub 2018 Mar 20.
9
Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.全身免疫炎症指数作为一种有用的预后指标可预测接受新辅助化疗的晚期胃癌患者的生存情况。
Cancer Manag Res. 2017 Dec 14;9:849-867. doi: 10.2147/CMAR.S151026. eCollection 2017.
10
Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series.新辅助化疗前后胃癌分期中的内镜超声检查。与临床系列中的PET-CT对比。
United European Gastroenterol J. 2017 Aug;5(5):641-647. doi: 10.1177/2050640616684697. Epub 2016 Dec 12.
Zotero 插件